Q4 2025 Sangamo Therapeutics Inc Earnings Call Transcript
Key Points
- Sangamo Therapeutics Inc (SGMO) announced positive top-line results from the STAR study in Fabry disease, which may serve as the primary basis for FDA approval under an accelerated pathway.
- The company initiated a rolling submission of a Biologics License Agreement (BLA) to the FDA for ST-920, marking its first-ever wholly-owned BLA submission.
- Sangamo secured a third neurology capsid license agreement with Eli Lilly, enhancing its position as a collaborator of choice for neurotropic capsids.
- The company raised over $130 million in funding through non-dilutive license fees, milestone payments, and equity financing since the start of 2025.
- Sangamo received Fast Track designation from the FDA for SC503, its investigational treatment for small fiber neuropathy, highlighting the potential to address unmet medical needs.
- Sangamo Therapeutics Inc (SGMO) faces regulatory and market uncertainty, impacting its operations and strategic decisions.
- The company is experiencing delays in the completion of Chemistry, Manufacturing, and Controls (CMC) activities, affecting the timeline for BLA submission.
- Sangamo is managing limited cash resources, which necessitates careful financial management and impacts its ability to advance projects.
- The company has not yet secured a commercial partner for its Fabry program, which remains a critical focus for its long-term cash runway.
- Discussions with potential partners for Fabry commercialization are complex and time-consuming, leading to frustration over the prolonged process.
Good afternoon, and welcome to the Sangamo Therapeutics fourth-quarter and full-year 2025 teleconference call. Please be advised that today's conference is being recorded.
I would now like to turn the conference over to your speaker today, Louise Wilkie, Head of Investor Relations and Corporate Communications. Please go ahead.
Thank you. Good afternoon, everyone. Thank you for joining us on the call today. On this call are several members of the Sangamo Executive Leadership Team, including Sandy McRae, Chief Executive Officer, Natalie DuBois String Fellow, Chief Development Officer, Nikunj Jain, Interim Chief Financial Officer, and Greg Davis, Head of Research and Technology.
Slides from our corporate presentation can be found on our website, sangamo.com, and under the Presentations page of the Investors and Media section.
This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
